News - Myeloma Patients Europe

Latest News

MPE webinar on ASH 2019 myeloma and AL amyloidosis highlights

December 20, 2019

Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in…

ASH 2019 myeloma highlights

December 10, 2019

More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December…

New data show HARMONY Alliance’s big data platform can improve the prognostic tool for myeloma patients

December 6, 2019

ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a…

Job offer – Senior Office Assistant

November 28, 2019

MPE is looking for a Senior Office Assistant. Would you like to join the MPE team? Apply for this job offer by sending your CV and motivation letter to Ananda Plate plate@mpeurope.org. Full time /…

Myeloma ASH 2019 preview

November 27, 2019

More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7…

In Memoriam of Lisa Kotschi

November 25, 2019

It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019.

The European Medicines Agency (EMA) recommends extension of indications for daratumumab

October 21, 2019

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the drug daratumumab (Darzalex®, commercialised by…

European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myeloma

August 28, 2019

European Commission (EC) has approved elotuzumab –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who…

December

January 2025

February

MO
TU
WE
TH
FR
SA
SU

30
31
1
2
3
4
5

6
7
8
9
10
11
12

13
14
15
16
17
18
19

20
21
22
23
24
25
26

27
28
29
30
31
1
2

Events for January

31st

No Events

Latest News

January 2025

Events for January

1st

Events for January

2nd

Events for January

3rd

Events for January

4th

Events for January

5th

Events for January

6th

Events for January

7th

Events for January

8th

Events for January

9th

Events for January

10th

Events for January

11th

Events for January

12th

Events for January

13th

Events for January

14th

Events for January

15th

Events for January

16th

Events for January

17th

Events for January

18th

Events for January

19th

Events for January

20th

Events for January

21st

Events for January

22nd

Events for January

23rd

Events for January

24th

Events for January

25th

Events for January

26th

Events for January

27th

Events for January

28th

Events for January

29th

Events for January

30th

Events for January

31st

Myeloma Patients Europe AISBL

PopUp